The Sexual Wellness Protocol
A protocol that treats PT-141 as what it is: bremelanotide, an FDA-approved on-demand drug for low sexual desire in premenopausal women, with a 0.35-point desire effect over placebo, 40%-range nausea in the trials and a blood-pressure contraindication. Layer 0 is home blood pressure and a hormone, glucose and medication review, because most low desire has a cause this page does not treat. Layer 1 is zinc only for a confirmed deficiency. Layer 2 is bremelanotide at the approved dose and frequency limits. Layer 3 is intranasal oxytocin, kept optional because the controlled trial could not separate it from placebo. Graded C.
Daily Schedule
Timing and dosage for each step
Layer 0 — before anything: blood pressure at home on three mornings; morning testosterone, zinc and HbA1c; a medication review
15 mg
A measurement step, not a dose. Bremelanotide is contraindicated in uncontrolled hypertension and known cardiovascular disease, so the blood-pressure readings decide whether Layer 2 is open to you at all. Low testosterone, diabetes, SSRIs, beta-blockers and relationship factors are causes that PT-141 does not treat. The 15 mg is the Layer 1 zinc dose that follows only if serum zinc is low.
Layer 1 — with dinner, from week 0, ONLY if serum zinc is low or intake is clearly short
30 mg
15–30 mg zinc bisglycinate with food, away from copper. Zinc deficiency suppresses testosterone (restriction cut it from 39.9 to 10.6 nmol/L in young men; repletion raised it from 8.3 to 16.0 nmol/L in deficient elderly men). It corrects a deficiency; it is not an aphrodisiac for anyone replete. Give it 8 weeks before judging. Add 1–2 mg copper above 30 mg/day.
Layer 2 — subcutaneous, 45 minutes or more before anticipated activity; no more than one dose in 24 hours and eight a month
1.75 mg
1.75 mg is the approved Vyleesi dose. In two phase 3 trials (1,267 premenopausal women with HSDD) it raised sexual desire scores by 0.35 and lowered distress by 0.33 versus placebo; nausea, flushing and headache each affected 10% or more, 13% needed an anti-emetic and 8% quit for nausea. Transiently raises blood pressure and lowers heart rate for hours. Community use starts at 0.5–1 mg to test nausea; that is a tolerance choice, not a trial dose. Men: off-label; one RCT in sildenafil non-responders found a 33.5% vs 8.5% response.
Layer 3 — OPTIONAL, intranasal, 15–30 min before activity
40 mcg
24 IU (about 0.04 mg) intranasal. Labelled honestly: in the randomized crossover trial of long-term intranasal oxytocin in women with sexual dysfunction, oxytocin and placebo improved sexual function equally with no treatment effect; in 29 healthy couples a single 24 IU dose did not change drive, arousal or erection but increased orgasm intensity and post-sex contentment, mostly in men. Run it as a two-week experiment against your own baseline, not as a treatment.
Read This Before the Protocol
Low desire usually has a cause, and PT-141 does not treat causes. Low testosterone, poorly controlled diabetes, SSRIs and other antidepressants, beta-blockers, alcohol, untreated depression, sleep apnea and the state of the relationship each explain more cases than a melanocortin receptor does. Layer 0 is a short search for those, and if it finds one, the fix is upstream of this page. For men, the fertility-and-function route is the Male Vitality Protocol; for a testosterone number in the lower third, the Hormonal Optimization Stack.
The second thing to know is what the PT-141 trials showed. Bremelanotide is approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women. In the two phase 3 trials, 1,267 women injected 1.75 mg as needed for 24 weeks; sexual desire scores rose by 0.35 points and distress fell by 0.33 points more than on placebo, on scales that run to 6 and 4. Those are statistically solid, clinically modest effects. Nausea, flushing and headache each affected at least one in ten, 13% needed an anti-emetic, and 8% stopped because of nausea. In men it is off-label: one randomized trial in sildenafil non-responders found a positive response in 33.5% versus 8.5% on placebo. The full pharmacology is in PT-141: The Biochemistry of Libido.
The third: the oxytocin layer is here because people ask about it, not because a trial supports it. The randomized crossover trial of long-term intranasal oxytocin in women with sexual dysfunction found that oxytocin and placebo improved sexual function equally, with no treatment effect, and the partners of those women improved equally too. The one acute study in couples found no change in desire, arousal or erection, with an effect on orgasm intensity and post-sex contentment, mostly in men. This page keeps oxytocin as a labelled experiment against your own baseline.
Layer 0 — Find the Cause and Check the Pressure
| Check | Why |
|---|---|
| Home blood pressure, three mornings | Bremelanotide raises blood pressure transiently and is contraindicated in uncontrolled hypertension and known cardiovascular disease |
| Morning total testosterone (men and women), SHBG | Low testosterone is a cause with its own protocol |
| HbA1c, fasting glucose | Vascular and neuropathic sexual dysfunction starts here |
| Medication list | SSRIs, SNRIs, beta-blockers, finasteride, opioids, antipsychotics, hormonal contraception |
| Serum zinc | Decides whether Layer 1 applies at all |
| Mood, sleep, alcohol, the relationship | Not a blood test, and the largest effect sizes on this list |
If a cause turns up, treat it first. Starting PT-141 on top of an SSRI or untreated apnea gives you nausea and a masked diagnosis.
Who This Is For, and Who Should Not Run It
For: premenopausal women with persistent low desire that distresses them and has no identifiable cause, the group the drug was tested and approved in; men with psychogenic erectile dysfunction or non-response to PDE5 inhibitors who want to discuss a melanocortin agonist with a prescriber; couples who want to test oxytocin against their own baseline knowing the controlled trial was null.
Not for, without a clinician:
- Uncontrolled hypertension, known cardiovascular disease, or a high cardiovascular risk profile — the label contraindication.
- Pregnancy, trying to conceive, or breastfeeding.
- Oral naltrexone — bremelanotide slows gastric emptying and lowers its absorption; the label warns about it.
- Severe liver or kidney disease.
- Anyone using a research-grade peptide in place of the approved drug should understand that purity, dose and sterility are unverified; the trial numbers above describe the pharmaceutical product, not a vial.
The Layer Logic
| Layer | What | Evidence grade | Who |
|---|---|---|---|
| 0 — Find the cause | Blood pressure, hormones, glucose, medications | — | Everyone |
| 1 — Zinc 15–30 mg | Correct a deficiency | A for deficiency, not applicable otherwise | Low serum zinc only |
| 2 — Bremelanotide 1.75 mg | Central melanocortin agonist, on demand | A for HSDD in premenopausal women; B off-label in men | Those cleared at Layer 0 |
| 3 — Oxytocin 24 IU | Bonding and orgasm quality | C, optional; the controlled trial was null | A two-week self-experiment, if at all |
The protocol is graded C. The drug at its core is grade A for one indication, but the protocol as people run it, with a research-grade vial, an off-label population and an optional layer the trial could not separate from placebo, is not.
Layer 1 — Zinc, Only for a Shortfall
If serum zinc is low or your diet is clearly short of it (vegan, low meat, heavy sweating), take 15–30 mg of zinc bisglycinate with dinner, away from copper and iron, for eight weeks before judging. Zinc deficiency suppresses testosterone and repletion restores it: experimental zinc restriction in young men cut serum testosterone from 39.9 to 10.6 nmol/L over 20 weeks, and six months of supplementation in marginally deficient elderly men raised it from 8.3 to 16.0 nmol/L. In a replete person, zinc does nothing for desire and competes with copper; above 30 mg/day for more than a few weeks, add 1–2 mg of copper. Profile: Zinc.
Layer 2 — Bremelanotide, at the Approved Limits
Dose and timing. 1.75 mg subcutaneously into the abdomen or thigh at least 45 minutes before anticipated activity. No more than one dose in 24 hours and no more than eight in a month, the label limits; effects are described as lasting several hours. Community practice starts at 0.5–1 mg to find out whether nausea is tolerable before moving to the approved dose; treat that as a tolerance test, not as evidence that a lower dose works.
What to expect. In the phase 3 trials the effect was on desire and distress, not on erection or lubrication, and it appeared over weeks of on-demand use rather than on the first injection. Nausea affects roughly four in ten on first exposure and tends to ease with repeated use; flushing and headache are next. Transient rises in blood pressure and falls in heart rate follow each dose and resolve within hours, which is the basis for the cardiovascular contraindication. Focal darkening of skin on the face, gums or breasts has been reported with repeated dosing, more often in darker skin, and is a reason to stop.
Combining with PDE5 inhibitors. The old version of this page called the combination a formal contraindication; it is not on the label, and the only published co-administration study, intranasal PT-141 with sildenafil in men with erectile dysfunction, reported no new adverse events. The two drugs move blood pressure in opposite directions and the combination is essentially untested at the injectable dose, so it is a prescriber's decision, not a stack decision.
Nausea management. A light meal two hours before, good hydration, and a lower starting dose. Ondansetron is a prescription drug; if you need it to tolerate PT-141, that is a conversation with the prescriber, not a line in a protocol. Profile: PT-141 (Bremelanotide).
Layer 3 — Oxytocin, Labelled Honestly
Intranasal oxytocin at 24 IU, 15–30 minutes before activity, is the layer with the clearest negative trial on this page. In a randomized, placebo-controlled crossover of long-term intranasal oxytocin in premenopausal and postmenopausal women with sexual dysfunction, sexual function scores rose 26% on oxytocin and 31% on placebo, distress fell 36% and 45%, and there was no treatment, sequence or interaction effect; their male partners' sexual quality of life improved equally in both arms. The acute study in 29 healthy couples found that a single 24 IU dose did not alter sexual drive, arousal, erection or lubrication, but increased orgasm intensity and contentment after sex, more in men than women.
If you want to test it, do it as an experiment: two weeks of your own 1–5 ratings for desire, arousal, orgasm and closeness without it, then two weeks with it, then compare. Not for daily use, not in pregnancy, and not as a substitute for a conversation that the trial suggests is doing most of the work. Profile: Oxytocin.
What Is Deliberately Left Out
- PDE5 inhibitors as a layer. Prescription drugs for a prescriber; this page explains how they relate to PT-141, nothing more.
- Testosterone, DHEA, flibanserin. Hormones and a daily centrally acting drug with its own alcohol interaction; medical territory.
- "Libido stacks" of herbs. Maca and Tongkat Ali have their own pages and their own, separate evidence; mixing them with an injectable makes side effects unattributable.
Monitoring
| Marker | When | What you are looking for |
|---|---|---|
| Blood pressure | Three mornings before starting; before and 2–4 hours after the first three doses | Stays within your normal range; a sustained rise ends Layer 2 |
| Desire, arousal, orgasm, closeness, 1–5 | Weekly average, from two weeks before Layer 2 | A full-point change sustained over a month |
| Nausea, flushing, headache | Each dose | Easing with repeated use; persistent severe nausea is a stop |
| Skin pigmentation | Monthly | Any new darkening of face, gums or breasts: stop and see a clinician |
| Serum zinc, testosterone | Week 0; week 8–12 if supplementing or if low at baseline | Into range; then stop zinc or reduce |
Exit Criteria
- Blood pressure above your normal range after dosing, chest pain, severe headache: stop and see a clinician. Do not retry at a lower dose.
- Eight doses without a change in your weekly ratings: the drug is not the answer. Go back to Layer 0.
- Nausea that does not ease by the third or fourth dose: stop; the trial discontinuation rate for nausea was 8%, and you are allowed to be in it.
- New skin darkening: stop; it may not fully reverse.
- Oxytocin after two weeks with no difference against your baseline: drop it, as the trial predicts.